Business Context and Reporting Period
This Form 8-K is a current report filed by pSivida Corp. (not Eyepoint, Inc.) on August 1, 2012. The filing addresses a material event regarding the company's partnership with Alimera Sciences, Inc. concerning the drug candidate ILUVIEN for the treatment of diabetic macular edema.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory development and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the announcement that partner Alimera Sciences, Inc. intends to resubmit its application for ILUVIEN to the U.S. Food and Drug Administration (FDA). This resubmission will utilize data from two previously completed pivotal Phase III clinical trials, known as the FAME Study.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (Exhibit 99.1) confirming the resubmission strategy. No specific financial guidance or future earnings outlook is provided in this document.
Risks and Contingencies: The filing implies a contingency on the FDA's review of the resubmitted application. The success of the commercialization of ILUVIEN depends on regulatory approval, which remains uncertain until the FDA completes its review.
Investor Verification Checklist
- Verify the status of the ILUVIEN resubmission with the FDA and any subsequent regulatory decisions.
- Review the full text of the press release filed as Exhibit 99.1 for additional details on the FAME Study data.
- Confirm the nature of the commercial partnership agreement between pSivida Corp. and Alimera Sciences, Inc.
- Check for any subsequent filings regarding the outcome of the FDA review process.